Diabetes is among the strongest risk factors for macrovascular and microvascular complications, but many healthcare professionals concentrate on just treating high blood glucose in this patient population. In this animation, Dr Andreas Liebl provides a brief overview of why patients with type 2 diabetes are at increased risk for cardiovascular diseases, how this risk can be measured, and how it can be managed. Dr Andreas Liebl is Medical Director of the Center for Diabetes and Metabolism at the Fachklinik in Bad Heilbrunn, Germany.
Specialists including endocrinologists, diabetologists and cardiologists, and primary care physicians who have some experience with treating patients with type 2 diabetes.
After completing this educational activity, learners will be able to:
| Type of affiliation / financial interest | Name of commercial company |
|---|---|
| Advisory Board | Boehringer Ingelheim, Eli Lilly, Novo Nordisk |
| Speakers Bureau | AstraZenica, Boehringer ingelheim, Eli Lilly, Novo Nordisk, Sanofi |
Liberum IME staff, ACHL staff and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
ACHL requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires its speakers to disclose that a product is not labeled for the use under discussion.
Discussion of Off-Label, Investigational, or Experimental Drug Use: None
This independent educational activity is supported by an educational grant from Novo Nordisk. The educational content has been developed by Liberum IME in collaboration with an independent steering committee; Novo Nordisk had no influence on the content of this educational activity.
This module was accredited on the 29th November 2023 and will expire on the 29th November 2024.
The information and data provided in this program was updated and correct at the time of the program development, but may be subject to change.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Academy for Continued Healthcare Learning (ACHL) and Liberum IME. ACHL is accredited by the ACCME to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning (ACHL) designates this enduring material for up to 0.25 AMA PRA Category 1 Credits™. Physicians should claim credit commensurate with the extent of their participation in the activity.
The American Medical Association (AMA) has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credits™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMEC®s) should contact the UEMS at mutualrecognition@uems.eu
The content for this activity was developed independently of the ineligible companies. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantors.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis."
In this short animation Dr Andreas Liebl offers insights into how we can assess cardiovascular risk and make appropriate therapy choices when treating patients with type 2 diabetes
Dr Andreas Liebl explique comment nous pouvons évaluer le risque cardiovasculaire et faire des choix thérapeutiques appropriés lorsque nous traitons des patients atteints de diabète de type 2
En esta breve animación, el Dr. Andreas Liebl nos explica cómo podemos evaluar el riesgo cardiovascular y tomar las decisiones terapéuticas adecuadas cuando tratamos a pacientes con DT2.